Revolution Medicines, Inc.
RVMDW· Nasdaq
RVMDWRevolution Medicines, Inc.
Filed May 14, 2020 · 10-Q · 44 days after period end · 0001564590-20-025452
| Metric | Q1 2020 | Q1 2019 |
|---|---|---|
| Revenue | $11.55M | $13.17M |
| Net Income | -$19.52M | -$10.13M |
| EPS Diluted | -$0.74 | -$4.84 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Revolution Medicines, Inc. · CIK 1628171 · Engraved from SEC EDGAR
ended Mar 31, 2020 · filed May 14, 2020 · 44 d after period end
